• Novo Nordisk A/S, of Bagsvaerd, Denmark, said its ultra-long-lasting insulin degludec significantly reduced the rate of hypoglycemia at night in adults with Type II diabetes, while obtaining equivalent improvement in glucose control compared with insulin glargine over a 52-week period. Data from that Phase IIIa trial were presented at the American Diabetes Association meeting in Philadelphia.
To read more on related topics, click on one of the words below.